Can IMAAVY’s sustained control data reshape earlier treatment of generalized myasthenia gravis?
Discover what Johnson & Johnson’s new IMAAVY data mean for earlier gMG treatment, sustained control, safety and FcRn competition.
Pharma & Biotech
Pharma & Biotech
Regeneron’s cemdisiran enters FDA and EMA review for generalized myasthenia gravis
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis care with potential quarterly subcutaneous dosing.
Pharma & Biotech
Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis
Vyvgart now covers all adult gMG serotypes. Argenx gains a wider label, but payers and real-world durability remain the next test.
Medical Devices & Diagnostics
What KORU Medical’s RYSTIGGO delivery clearance means for subcutaneous infusion models
KORU Medical’s FreedomEDGE gets FDA clearance for RYSTIGGO delivery in clinics. Find out how this expands access to gMG therapy and reshapes infusion workflows.
Features & Analysis
Is twice-yearly dosing the future of autoimmune care? Inside Amgen’s UPLIZNA playbook for chronic neurology
When Amgen (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration had approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis (gMG), the industry’s attention snapped not just to the therapy’s mechanism but to its twice-yearly maintenance schedule. For patients, this marks a seismic shift away from the exhausting cycle of daily oral immunosuppressants
Pharma & Biotech
Can B-cell depletion change how we treat generalized myasthenia gravis?
Amgen has received approval from the United States Food and Drug Administration for Uplizna (inebilizumab-cdon) to treat adults with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle specific tyrosine kinase antibody positive. The greenlight makes Uplizna the first and only CD19-targeted B cell therapy approved for this patient population, introducing a twice-yearly dosing regimen